Lupin gets approval from FDA for generic drug for dementia

Published On 2015-11-04 05:09 GMT   |   Update On 2022-12-10 10:48 GMT
Advertisement
USFDA has recently given its approval to the pharma major Lupin to market generic Aricept tablets used for treatment of dementia.

The company's US subsidiary, Lupin Pharmaceuticals, would commence promoting the product shortly in the US, to grab a share of the lucrative Aricept US sales of $52.3 million (IMS MAT June 2015).

"...it has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai Inc's Aricept tablets," it added.
Advertisement

Lupin's Donepezil Hydrochloride Tablets are the AB rated generic equivalent of Eisai Inc's Aricept tablets and is indicated for the treatment of dementia of the Alzheimer's type.

In a separate filing, Lupin said it has also received final approval for its Blisovi 24 Fe Tablets from the US FDA to market a generic version of Warner Chilcott's Loestrin24 Fe Tablets.

Its US subsidiary Lupin Pharmaceuticals Inc would commence promoting the product shortly in the US, the company said in a statement.

Lupin's Blisovi 24 Fe Tablets are the AB rated generic equivalent of Warner Chilcott's Loestrin24 Fe Tablets.

The company said it is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Loestrin24 Fe had US sales of $56.8 million (IMS MAT June 2015).
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News